Aptose Q2 net loss $7.0M; cash $1.3M; CSRC okays TUS dose escalation to 160 mg

Aptose Biosciences Inc.

2025-Q2 EPS reported -$5.38

Net loss $7.0M ($2.76 per share) for Q2 2025, vs. $7.3M in Q2 2024; loss per share improved on higher share count.
Cash and equivalents $1.3M as of June 30, 2025; company says cash insufficient to fund operations, relying on Hanmi loan of up to $8.5M.
Safety Review Committee approved dose escalation of tuspetinib to 160 mg in TUS+VEN+AZA TUSCANY trial; 120 mg cohort all patients remain on study.
All 10 enrolled subjects in TUSCANY triplet remain on treatment; CRs achieved at 40 mg and 80 mg doses across diverse AML mutations.
Selected EY as new auditor; annual meeting reconvened for August 22, 2025 to vote on appointment.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.